$KANT
KINETA, INC./DE

2021 Q1 Form 10-K Financial Statement

#000119312521101509 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020
Revenue $3.532M $6.900M $6.896M
YoY Change 37.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.050M -$610.0K $11.88M
YoY Change 68.52% -120.0% -14.16%
% of Gross Profit
Research & Development $6.779M $38.30M $22.31M
YoY Change 34.8% 320.83% -2.87%
% of Gross Profit
Depreciation & Amortization $200.0K $640.0K $800.0K
YoY Change 0.0% 82.86% -24.31%
% of Gross Profit
Operating Expenses $12.83M $35.30M $62.53M
YoY Change 81.72% 190.37% 108.21%
Operating Profit -$9.299M -$55.63M
YoY Change 31.7% 85.25%
Interest Expense $488.0K -$2.180M $1.900M
YoY Change 7.49% -1138.1% 57.15%
% of Operating Profit
Other Income/Expense, Net $617.0K $40.00K -$1.856M
YoY Change -252.72% -53.49% 57.56%
Pretax Income -$8.680M -$30.55M -$57.49M
YoY Change -12.15% 157.59% -2.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.682M -$30.55M -$57.49M
YoY Change 16.3% 157.68% 84.2%
Net Earnings / Revenue -245.81% -442.75% -833.63%
Basic Earnings Per Share
Diluted Earnings Per Share -$851.8K -$18.63M -$24.46M
COMMON SHARES
Basic Shares Outstanding 10.19M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.87M $85.30M $85.30M
YoY Change 10.11% 455.04% 22.73%
Cash & Equivalents $52.10M $80.80M $80.80M
Short-Term Investments $10.77M $4.498M $4.500M
Other Short-Term Assets $3.800M $2.300M $2.300M
YoY Change 52.0% 64.29% 64.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $66.64M $87.58M $87.60M
YoY Change 11.81% 441.49% 23.55%
LONG-TERM ASSETS
Property, Plant & Equipment $685.0K $874.0K $24.60M
YoY Change -94.61% -14.06% 89.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $400.0K $400.0K $400.0K
YoY Change
Other Assets $2.100M $2.300M $2.300M
YoY Change 162.5% 187.5% 187.5%
Total Long-Term Assets $25.65M $27.25M $27.20M
YoY Change 90.01% 1803.21% 97.1%
TOTAL ASSETS
Total Short-Term Assets $66.64M $87.58M $87.60M
Total Long-Term Assets $25.65M $27.25M $27.20M
Total Assets $92.29M $114.8M $114.8M
YoY Change 26.25% 552.25% 35.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.947M $7.384M $7.400M
YoY Change 62.25% 287.61% 221.74%
Accrued Expenses $3.549M $7.851M $12.30M
YoY Change -39.85% 224.29% 53.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $3.675M $2.891M $3.100M
YoY Change
Total Short-Term Liabilities $18.46M $30.86M $30.90M
YoY Change 125.16% 522.26% 200.0%
LONG-TERM LIABILITIES
Long-Term Debt $11.41M $13.24M $13.30M
YoY Change -8.52%
Other Long-Term Liabilities $162.0K $14.50M $14.50M
YoY Change -98.62% 20.83% 20.83%
Total Long-Term Liabilities $11.58M $13.24M $27.80M
YoY Change -1.07% -8.52% 131.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.46M $30.86M $30.90M
Total Long-Term Liabilities $11.58M $13.24M $27.80M
Total Liabilities $43.36M $58.63M $58.60M
YoY Change 117.87% 196.0% 162.78%
SHAREHOLDERS EQUITY
Retained Earnings -$156.5M -$147.8M
YoY Change 52.35%
Common Stock $10.00K $10.00K
YoY Change -80.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.93M $56.21M $56.20M
YoY Change
Total Liabilities & Shareholders Equity $92.29M $114.8M $114.8M
YoY Change 26.25% 552.25% 35.54%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$8.682M -$30.55M -$57.49M
YoY Change 16.3% 157.68% 84.2%
Depreciation, Depletion And Amortization $200.0K $640.0K $800.0K
YoY Change 0.0% 82.86% -24.31%
Cash From Operating Activities -$22.29M $11.23M -$17.94M
YoY Change 169.08% -196.31% -34.07%
INVESTING ACTIVITIES
Capital Expenditures $6.000K -$250.0K $246.0K
YoY Change -96.47% -61.44%
Acquisitions
YoY Change
Other Investing Activities -$6.270M -$8.200M $31.29M
YoY Change -130.19% 329.32% -32.08%
Cash From Investing Activities -$6.275M -$8.450M $31.04M
YoY Change -631.78% 344.74% -6.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $33.60M
YoY Change 858.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -142.0K 55.11M 55.54M
YoY Change 61.36% 1580.18% 1735.9%
NET CHANGE
Cash From Operating Activities -22.29M 11.23M -17.94M
Cash From Investing Activities -6.275M -8.450M 31.04M
Cash From Financing Activities -142.0K 55.11M 55.54M
Net Change In Cash -28.71M 57.89M 68.64M
YoY Change 299.18% -663.13% 657.02%
FREE CASH FLOW
Cash From Operating Activities -$22.29M $11.23M -$17.94M
Capital Expenditures $6.000K -$250.0K $246.0K
Free Cash Flow -$22.29M $11.48M -$18.18M
YoY Change 163.74% -198.46% -34.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1350000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
53235000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
246000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
638000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
35939000
CY2020 ymtx Payments Of Merger Transaction Costs
PaymentsOfMergerTransactionCosts
1520000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31041000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33250000
CY2020 ymtx Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
1123000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
14750000
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10767000
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
72000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2154000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
642000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17938000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27208000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4495000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19347000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
347000
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
958000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55536000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3025000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68639000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9067000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
533000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2802000
CY2019 ymtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-986000
CY2020 us-gaap Interest Expense
InterestExpense
1900000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-72000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-30031000
CY2020 ymtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1688000
CY2019 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
418000
CY2020 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1497000
CY2019 ymtx Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
-3000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-72000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-511000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
318000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
535000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
316000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1545000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2266000
CY2019 ymtx Noncash Lease Expense
NoncashLeaseExpense
1049000
CY2020 ymtx Noncash Lease Expense
NoncashLeaseExpense
2501000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1057000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
770000
CY2019 us-gaap Profit Loss
ProfitLoss
-31209000
CY2020 us-gaap Profit Loss
ProfitLoss
-57487000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31201000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57487000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-31209000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-57487000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1178000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1856000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-511000
CY2019 ymtx Interest Incomeand Other Income Expense Net
InterestIncomeandOtherIncomeExpenseNet
-530000
CY2020 ymtx Interest Incomeand Other Income Expense Net
InterestIncomeandOtherIncomeExpenseNet
28000
CY2019 us-gaap Interest Expense
InterestExpense
1209000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-55631000
CY2019 us-gaap Operating Expenses
OperatingExpenses
30031000
CY2020 us-gaap Operating Expenses
OperatingExpenses
62527000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7062000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11881000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22969000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22310000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6896000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17606000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114835000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-91900000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
56207000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97020000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147810000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
204007000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Liabilities
Liabilities
19807000
CY2020Q4 us-gaap Liabilities
Liabilities
58628000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
116000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
48000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14479000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14470000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13237000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4960000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30864000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8104000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
343000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
291000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4468000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2891000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2421000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7851000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1905000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7384000
CY2019Q4 us-gaap Assets
Assets
17606000
CY2020Q4 us-gaap Assets
Assets
114835000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2066000
CY2019Q4 us-gaap Deposit Assets
DepositAssets
40000
CY2020Q4 us-gaap Deposit Assets
DepositAssets
386000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
275000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1017000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
874000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
16174000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
87581000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
125000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
681000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2264000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
1347000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
4498000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14021000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80819000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14246000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5179000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
82885000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1287000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
910000
CY2020 ymtx Additions To Property And Equipment Under Finance Lease
AdditionsToPropertyAndEquipmentUnderFinanceLease
102000
CY2020 ymtx Transaction Costs Included In Accounts Payable And Accrued Expenses
TransactionCostsIncludedInAccountsPayableAndAccruedExpenses
1169000
CY2020 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
24662000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
2100000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
200000
CY2020Q4 ymtx Number Of Shares Owned By Acquiree
NumberOfSharesOwnedByAcquiree
2708537
CY2020Q4 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
22.20
CY2020Q4 ymtx Fair Value Of Shares Owned By Acquiree
FairValueOfSharesOwnedByAcquiree
60130000
CY2020Q4 ymtx Fair Value Of Stock Options Assumed
FairValueOfStockOptionsAssumed
471000
CY2020Q4 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
2689000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83427000
CY2020Q4 ymtx Preferred Unit Warrant Liability Non Current
PreferredUnitWarrantLiabilityNonCurrent
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.061
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.011
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.278
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23142000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2324000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
312000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
360000
CY2019Q4 ymtx Deferred Tax Assets Capitalized Intellectual Property Cost
DeferredTaxAssetsCapitalizedIntellectualPropertyCost
109000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14493000
CY2019Q4 ymtx Preferred Unit Warrant Liability Non Current
PreferredUnitWarrantLiabilityNonCurrent
261000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4498000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4498000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1347000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1347000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2053000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2609000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1592000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4295000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1318000
CY2020Q4 ymtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1780000
CY2019Q4 ymtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
689000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
987000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
215000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
789000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
199000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16123000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2891000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 ymtx Debt Instrument Carrying Amount Noncurrent
DebtInstrumentCarryingAmountNoncurrent
13232000
CY2019Q4 ymtx Debt Instrument Carrying Amount Noncurrent
DebtInstrumentCarryingAmountNoncurrent
15000000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
348000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
539000
CY2020Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
353000
CY2019Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
9000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2891000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6305000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6341000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
586000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16123000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
99986
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
370000
CY2019Q4 ymtx Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
79000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
103000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
147680000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26799000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141672000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26724000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2354143
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.57
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.71
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1044947
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2121843
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
915871
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
3097000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1101000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
271000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
583000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
361000
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
896000
CY2020 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
20000
CY2019 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
55000
CY2020 ymtx Finance Lease Cost
FinanceLeaseCost
381000
CY2019 ymtx Finance Lease Cost
FinanceLeaseCost
951000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
2461000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1131000
CY2020 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
20000
CY2019 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
55000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
347000
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
958000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10219000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
469000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
102000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10D
CY2020Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M3D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0901
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0646
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5997000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
173000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6173000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
49000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2977000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1931000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1985000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4841000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23904000
CY2020Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
222000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4957000
CY2020Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
8000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
18947000
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
214000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23678000
CY2020Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
23877000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
166000
CY2020Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
19161000
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Entity Registrant Name
EntityRegistrantName
YUMANITY THERAPEUTICS, INC.
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001445283
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10193831
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10193831
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
60454412
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2020 dei Trading Symbol
TradingSymbol
YMTX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity File Number
EntityFileNumber
001-38549
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8436652
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2020 dei City Area Code
CityAreaCode
617
CY2020 dei Local Phone Number
LocalPhoneNumber
409-5300
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 4410
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-62244000
CY2019 ymtx Adjustments To Common Units Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToCommonUnitsSharebasedCompensationRequisiteServicePeriodRecognitionValue
1545000
CY2019 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
8000
CY2020 ymtx Adjustments To Common Units Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToCommonUnitsSharebasedCompensationRequisiteServicePeriodRecognitionValue
2266000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
189000
CY2020Q4 ymtx Merger Agreement Exchange Ratio
MergerAgreementExchangeRatio
0.2108
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
15401
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.68
CY2020 ymtx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
0
CY2019 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-75000
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
346000
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
199000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
CY2020 ymtx Conversion Of Preferred Unit Warrants Into Common Stock Warrants
ConversionOfPreferredUnitWarrantsIntoCommonStockWarrants
189000
CY2020 ymtx Conversion Of Preferred Units To Common Stock
ConversionOfPreferredUnitsToCommonStock
104237000
CY2020 ymtx Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
1993000
CY2019 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
72000
CY2019 ymtx Issuance Of Preferred Unit Warrant In Connection With Loan
IssuanceOfPreferredUnitWarrantInConnectionWithLoan
223000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33597000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8104000
CY2020 ymtx Gain On Sale Of Property And Equipment
GainOnSaleOfPropertyAndEquipment
2000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
28336000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1179000
CY2020 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
28336000
CY2020Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
250000
CY2020 us-gaap Dividends
Dividends
0
CY2020 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
471000
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
31604000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
14008
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
8.68
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
790
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
8.68
CY2020Q4 ymtx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exchange Of Incentive Units For Restricted Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangeOfIncentiveUnitsForRestrictedCommonStock
-603
CY2020Q4 ymtx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exchange Of Incentive Units For Restricted Common Stock Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangeOfIncentiveUnitsForRestrictedCommonStockWeightedAverageGrantDateFairValue
8.68
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.709
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.721
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y9M18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y9M18D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
815885
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
84758
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150232
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
944961
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
944961
CY2020Q4 ymtx Merger Agreement Exchange Ratio
MergerAgreementExchangeRatio
0.2108
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
944961
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
5836000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
75000
CY2020Q4 ymtx Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
4670000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.71
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.51
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.99
CY2020Q4 ymtx Share Based Compensation Arrangements By Share Based Payment Award Options Assumed With Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedWithMergerWeightedAverageExercisePrice
68.48
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.70
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.70
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.70
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M27D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M14D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M14D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M14D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1998000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6522000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6522000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6522000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2266000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1545000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.39
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.10
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5200000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3M
CY2019Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M1D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0811
CY2019Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0609
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50790000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31209000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.016
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.012
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.135
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.104
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
122460000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
18654000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
184000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
539000
CY2020Q4 ymtx Deferred Tax Assets Capitalized Intellectual Property Cost
DeferredTaxAssetsCapitalizedIntellectualPropertyCost
89000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1084000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
172000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10193831
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Debt Securities Held To Maturity Threshold Period Past Due
DebtSecuritiesHeldToMaturityThresholdPeriodPastDue
P1Y
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6008000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
75000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2020 ymtx Gain On Extinguishment Of Class B Preferred Units
GainOnExtinguishmentOfClassBPreferredUnits
6697000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of estimates </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of common units prior to the Merger and the valuation of stock/unit-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Actual results may differ from those estimates or assumptions. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of credit risk and of significant suppliers </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. At times the Company may maintain cash and investment balances in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials related to its discovery programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of&#160;long-lived&#160;assets </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its long-lived assets, which consist primarily of property and equipment and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not record any impairment losses on&#160;long-lived&#160;assets during the years ended December&#160;31, 2020 or 2019. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26724000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18044000
CY2020 ymtx Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
7777000
CY2019 ymtx Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
8680000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Acquisition
UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
107171000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Acquisition
UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141672000
CY2020Q4 ymtx Share Based Compensation Arrangement By Share Based Payment Award Options Shares Assumed With Merger
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAssumedWithMerger
194550
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00

Files In Submission

Name View Source Status
0001193125-21-101509-index-headers.html Edgar Link pending
0001193125-21-101509-index.html Edgar Link pending
0001193125-21-101509.txt Edgar Link pending
0001193125-21-101509-xbrl.zip Edgar Link pending
d51046d10k.htm Edgar Link pending
d51046dex1014.htm Edgar Link pending
d51046dex211.htm Edgar Link pending
d51046dex231.htm Edgar Link pending
d51046dex311.htm Edgar Link pending
d51046dex312.htm Edgar Link pending
d51046dex321.htm Edgar Link pending
d51046dex42.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g51046g10v10.jpg Edgar Link pending
g51046g11v11.jpg Edgar Link pending
g51046g17v17.jpg Edgar Link pending
g51046g18v18.jpg Edgar Link pending
g51046g19v19.jpg Edgar Link pending
g51046g21v21.jpg Edgar Link pending
g51046g22v01.jpg Edgar Link pending
g51046g22v02.jpg Edgar Link pending
g51046g23v00.jpg Edgar Link pending
g51046g23v01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ymtx-20201231.xml Edgar Link completed
ymtx-20201231.xsd Edgar Link pending
ymtx-20201231_cal.xml Edgar Link unprocessable
ymtx-20201231_def.xml Edgar Link unprocessable
ymtx-20201231_lab.xml Edgar Link unprocessable
ymtx-20201231_pre.xml Edgar Link unprocessable